Shopping Cart 0
Cart Subtotal
USD 0

Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1. The company's gene therapy vectors used in its programs are engineered using adeno-associated virus. Spark's SPK-RPE65 is intentended to cure rare blinding conditions caused by mutations in the RPE65 gene. The company develops gene therapy products for the treatment of debilitating genetic diseases such as inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. It collaborates with pharma and biotech companies for its research and development activities. Spark is headquartered in Philadelphia, Pennsylvania, the US.

Spark Therapeutics Inc (ONCE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Spark Therapeutics Raises USD73 Million in Series B Financing 14

Spark Therapeutics Raises USD 50 Million In Venture Financing 16

Partnerships 17

Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 17

Licensing Agreements 18

Novartis Enters into Licensing and Supply Agreement with Spark Therapeutics 18

Spark Therapeutics Enters into Licensing Agreement with Genethon 19

Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 20

Pfizer Amends Licensing Agreement with Spark Therapeutics 22

Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 24

Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 25

Spark Therapeutics Amends Licensing Agreement with University of Iowa Research Foundation 26

Spark Therapeutics Enters into Licensing Agreement with Children's Hospital of Philadelphia 28

Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 29

Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 30

Equity Offering 31

Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares 31

Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 33

Spark Therapeutics Raises USD181 Million in Public Offering of Shares 35

Spark Therapeutics Raises USD107 Million in Public Offering of Shares 37

Genable Tech to Raise USD15.7 Million in Financing 39

Spark Therapeutics Raises USD185 Million in IPO 40

Asset Transactions 42

JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 42

Acquisition 43

Spark Therapeutics Acquires Genable Technologies for USD15.3 Million 43

Spark Therapeutics Inc-Key Competitors 44

Spark Therapeutics Inc-Key Employees 45

Spark Therapeutics Inc-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Strategy And Business Planning 47

Oct 11, 2018: Governor Wolf Announces Spark Therapeutics to Expand in West Philadelphia with New Facility, 500 New Jobs 47

Financial Announcements 48

Aug 07, 2018: Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress 48

May 08, 2018: Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress 51

Feb 20, 2018: Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress 53

Nov 07, 2017: Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress 55

Aug 02, 2017: Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress 57

May 09, 2017: Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress 60

Feb 22, 2017: Spark Therapeutics Reports 2016 Financial Results and Business Highlights 62

Corporate Communications 64

Jan 04, 2018: Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors 64

Sep 25, 2017: Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer 65

Product News 66

12/19/2017: FDA Approves Spark Therapeutics LUXTURNA (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy 66

11/02/2017: Spark Therapeutics to Participate in Multiple Upcoming Conferences 68

10/12/2017: FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease 69

07/10/2017: Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress 71

06/23/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress 73

04/06/2017: Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium 74

04/04/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium 75

03/26/2018: Boy with Inherited Blindness First to Receive FDA-Approved Gene Therapy at Bascom Palmer 76

03/21/2018: Childrens Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapy 77

03/20/2018: Mass. Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease 78

03/05/2018: Horizon Blue Cross Blue Shield Provides Update on Voretigene neparvovec-rzyl (Luxturna) 79

01/03/2018: Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment 80

01/03/2018: Spark's Gene Therapy Treatment for Blindness LUXTURNA to Cost USD 850,000 83

Product Approvals 85

Oct 19, 2017: Spark Therapeutics: Gene therapy continues to advance 85

Jul 31, 2017: Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA (voretigene neparvovec) 86

Jul 20, 2017: Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA (voretigene neparvovec) from FDA 88

Jul 17, 2017: Spark Therapeutics' Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA 89

May 18, 2017: Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene 91

Mar 01, 2017: Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency 92

Clinical Trials 93

Oct 08, 2018: Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate 93

Feb 23, 2018: Spark Therapeutics to Participate in Multiple Conferences in March 94

Nov 10, 2017: Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease 95

Oct 12, 2017: Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy 97

Sep 06, 2017: Spark Therapeutics Announces Publication of Study Confirming Novel Tests Validity, Reliability and Ability to Detect Change in Functional Vision 99

Jul 13, 2017: Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec 101

Jan 09, 2017: Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy 103

Appendix 105

Methodology 105

About GlobalData 105

Contact Us 105

Disclaimer 105


List Of Figure

List of Figures

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Spark Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Spark Therapeutics Raises USD73 Million in Series B Financing 14

Spark Therapeutics Raises USD 50 Million In Venture Financing 16

Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 17

Novartis Enters into Licensing and Supply Agreement with Spark Therapeutics 18

Spark Therapeutics Enters into Licensing Agreement with Genethon 19

Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 20

Pfizer Amends Licensing Agreement with Spark Therapeutics 22

Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 24

Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 25

Spark Therapeutics Amends Licensing Agreement with University of Iowa Research Foundation 26

Spark Therapeutics Enters into Licensing Agreement with Children's Hospital of Philadelphia 28

Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 29

Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 30

Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares 31

Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 33

Spark Therapeutics Raises USD181 Million in Public Offering of Shares 35

Spark Therapeutics Raises USD107 Million in Public Offering of Shares 37

Genable Tech to Raise USD15.7 Million in Financing 39

Spark Therapeutics Raises USD185 Million in IPO 40

JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 42

Spark Therapeutics Acquires Genable Technologies for USD15.3 Million 43

Spark Therapeutics Inc, Key Competitors 44

Spark Therapeutics Inc, Key Employees 45

Spark Therapeutics Inc, Subsidiaries 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Spark Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.